Blinatumomab, Inotuzumab Ozogamicin, and Chemotherapy for Acute Lymphoblastic Leukemia
Phase 2
80
about 10 years
14+
1 site in TX
What this study is about
This trial is testing if blinatumomab, inotuzumab ozogamicin, and combination chemotherapy are effective as the first treatment for patients with B acute lymphoblastic leukemia. This new approach may offer a better chance of success than standard chemotherapy alone.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Laboratory Biomarker Analysis
- 2.Receive Blinatumomab
- 3.Receive Inotuzumab Ozogamicin
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
blinatumomab, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), cytarabine, dexamethasone, Antineoplastic Agent [TC] (Topoisomerase 2 Inhibitors), inotuzumab ozogamicin, mercaptopurine, methotrexate
injection, intravenous, infusion, injection (Injection), ocular, oral (Oral Tablet), oral
Primary: Relapse-free survival (RFS)
Secondary: Incidence of adverse events, Overall response rate, Overall survival
Oncology